Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Subscribe To Our Newsletter & Stay Updated
